Key result
Anthracycline-based chemotherapy was associated with a short-term increase in pulse-wave-velocity of 4.21 m/s, indicating increased arterial stiffness that may partially reverse after therapy termination.
Why the study?
Anthracycline-based chemotherapy has been proposed to increase arterial stiffness, but the time-dependency of these effects remains unclear.
Does anthracycline-based chemotherapy increase markers of central aortic stiffness in cancer patients?
Systematic Review (n=282)
Does anthracycline-based chemotherapy increase markers of central aortic stiffness in cancer patients?
Mean Difference: 4.21 (95% CI -0.19–8.61)
Anthracycline-based chemotherapy is associated with a short-term increase in arterial stiffness that appears to be partly reversible after therapy termination.
Short-term anthracycline chemotherapy increases PWV 2.05 m/s; extends evidence for time-dependent arterial stiffening in cancer patients.
Background and Aims Anthracycline-based chemotherapy (Anth-bc) has been proposed to increase arterial stiffness, however, the time-dependency of these effects remain unclear. This systematic review and meta-analysis aimed to investigate the time-dependent effect of Anth-bc on markers of central aortic stiffness, namely aortic distensibility (AD) and pulse-wave-velocity (PWV) in cancer patients. Methods An extensive literature search without language restrictions was performed to identify all studies presenting longitudinal data on the effect of Anth-bc on either AD and/or central PWV in cancer patients of all ages. An inverse-variance weighted random-effect model was performed with differences from before to after chemotherapy, as well as for short vs. mid-term effects. Results Of 1811 articles identified, 6 observational studies with a total of 282 patients (median age 51±11; 70% women) were included, of which four studies measured AD and five PWV. Short-term (3-4 months), there was a clinically meaningful increase in arterial stiffness, namely an increase in PWV of 4.21 m/s (95%CI -0.19; 8.61) and a decrease in AD of -1.49 mmHg-1 (-3.25; 0.27) but a much smaller effect was observed mid-term (6-12 months) for PWV of 1.05 m/s (-1.45; 3.55) and AD of -0.37 mmHg-1 (-1.13; 0.39). There was considerable heterogeneity among the studies. Conclusions Results from this analysis suggest that in the short-term, Anth-bc increases arterial stiffness, but that these changes may partly be reversible after therapy termination. Future studies need to elucidate the long-term consequences of Anth-bc on arterial stiffness, by performing repeated follow-up measurements after Anth-bc termination.
No takes yet. Share an insight, caveat, or question.
Schneider et al. (2021) conducted a systematic review in Cancer (n=282). Anthracycline-based chemotherapy vs. Baseline (pre-chemotherapy) was evaluated on Short-term (3-4 months) change in central pulse-wave-velocity (PWV) (MD 4.21 m/s, 95% CI -0.19 to 8.61). Anthracycline-based chemotherapy was associated with a short-term increase in pulse-wave-velocity of 4.21 m/s, indicating increased arterial stiffness that may partially reverse after therapy termination.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: